In Vitro Characterization of GS-8374, a Novel Phosphonate-Containing Inhibitor of HIV-1 Protease with a Favorable Resistance Profile
- 1 April 2011
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (4), 1366-1376
- https://doi.org/10.1128/aac.01183-10
Abstract
GS-8374 is a novel bis-tetrahydrofuran HIV-1 protease (PR) inhibitor (PI) with a unique diethylphosphonate moiety. It was selected from a series of analogs containing various di(alkyl)phosphonate substitutions connected via a linker to the para position of a P-1 phenyl ring. GS-8374 inhibits HIV-1 PR with high potency (Ki = 8.1 pM) and with no known effect on host proteases. Kinetic and thermodynamic analysis of GS-8374 binding to PR demonstrated an extremely slow off rate for the inhibitor and favorable contributions of both the enthalpic and entropic components to the total free binding energy. GS-8374 showed potent antiretroviral activity in T-cell lines, primary CD4+ T cells (50% effective concentration [EC50] = 3.4 to 11.5 nM), and macrophages (EC50 = 25.5 nM) and exhibited low cytotoxicity in multiple human cell types. The antiviral potency of GS-8374 was only moderately affected by human serum protein binding, and its combination with multiple approved antiretrovirals showed synergistic effects. When it was tested in a PhenoSense assay against a panel of 24 patient-derived viruses with high-level PI resistance, GS-8374 showed lower mean EC50s and lower fold resistance than any of the clinically approved PIs. Similar to other PIs, in vitro hepatic microsomal metabolism of GS-8374 was efficiently blocked by ritonavir, suggesting a potential for effective pharmacokinetic boosting in vivo. In summary, results from this broad in vitro pharmacological profiling indicate that GS-8374 is a promising candidate to be further assessed as a new antiretroviral agent with potential for clinical efficacy in both treatment-naïve and -experienced patients.Keywords
This publication has 49 references indexed in Scilit:
- GS-8374, a Novel HIV Protease Inhibitor, Does Not Alter Glucose Homeostasis in Cultured Adipocytes or in a Healthy-Rodent Model SystemAntimicrobial Agents and Chemotherapy, 2011
- The evolution of HIV treatment guidelines: Current state-of-the-art of ARTAntiviral Research, 2010
- Human Immunodeficiency Virus in an Aging Population, a Complication of SuccessJournal of the American Geriatrics Society, 2009
- In Vitro Antiviral Activity of the Novel, Tyrosyl-Based Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor Brecanavir (GW640385) in Combination with Other Antiretrovirals and against a Panel of Protease Inhibitor-Resistant HIVAntimicrobial Agents and Chemotherapy, 2007
- A Novel Substrate-Based HIV-1 Protease Inhibitor Drug Resistance MechanismPLoS Medicine, 2007
- Suppression of HIV-1 Protease Inhibitor Resistance by Phosphonate-mediated Solvent AnchoringJournal of Molecular Biology, 2006
- Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profilesBioorganic & Medicinal Chemistry Letters, 2005
- Endoplasmic Reticulum Stress Links Dyslipidemia to Inhibition of Proteasome Activity and Glucose Transport by HIV Protease InhibitorsPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2005
- The Binding Energetics of First- and Second-Generation HIV-1 Protease Inhibitors: Implications for Drug DesignArchives of Biochemistry and Biophysics, 2001
- Combination Antiretroviral Therapy and Recent Declines in AIDS Incidence and MortalityThe Journal of Infectious Diseases, 1999